Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy Virtual 2020 | MRD as a tool to discontinue therapy in MM?

Luciano Costa • 11 May 2020
COMy Virtual 2020
Multiple Myeloma Antibodies Carfilzomib Daratumumab Dexamethasone Isatuximab Lenalidomide
MASTER

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses measurable residual disease (MRD) as a tool to discontinue therapy in multiple myeloma (MM). Dr Costa reveals that the next desired development in MM is to be able to use the dynamic prognostic information that MRD provides and repurpose it to make treatment decisions. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Luciano Costa

CA057-003 trial preliminary results: mezigdomide in novel combinations for R/R multiple myeloma 4:04
CA057-003 trial preliminary results: mezigdomide in novel combinations for R/R multiple myeloma
Luciano Costa • 13 Dec 2024
Implications of MRD progression in patients with NDMM treated with quadruplet therapy & autoSCT 4:50
Implications of MRD progression in patients with NDMM treated with quadruplet therapy & autoSCT
Luciano Costa • 13 Dec 2024
Elranatamab vs real-world treatments in triple-class refractory myeloma: insights from MagnetisMM-3 3:24
Elranatamab vs real-world treatments in triple-class refractory myeloma: insights from MagnetisMM-3
Luciano Costa • 13 Dec 2024
Strategies to optimize the outcomes of earlier-line patients treated with CAR T-cell therapy 3:01
Strategies to optimize the outcomes of earlier-line patients treated with CAR T-cell therapy
Luciano Costa • 26 Sep 2024

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals